Quick answer
How do laboratories test whether MOTS-c acts through AMPK? The original 2015 study reported that MOTS-c inhibits the folate cycle and its linked de novo purine biosynthesis, leading to activation of AMP-activated protein kinase (AMPK). Later studies used a pharmacological AMPK inhibitor to test dependence, and a 2018 study reported nuclear gene regulation by MOTS-c in an AMPK-dependent manner under metabolic stress. This article is a methods guide: which readouts show AMPK activity, what the standard activator and inhibitor tool compounds can and cannot tell you, and how to design controls. It summarizes published cell and animal work only. MOTS-c is supplied for laboratory research use only.
The hypothesis in brief
AMPK is described as a crucial cellular energy sensor that, once activated by falling energy status, promotes ATP production by increasing catabolic activity and conserves ATP by switching off biosynthetic pathways.[1] The MOTS-c hypothesis connects this sensor to a mitochondrial-encoded peptide: in the 2015 report, the peptide's cellular actions inhibit the folate cycle and de novo purine biosynthesis, leading to AMPK activation, with skeletal muscle as the apparent primary target organ.[2] The peptide profile is in the MOTS-c research overview, and background on the pathway in MOTS-c AMPK pathway research background. This page takes a narrower view: how the claim is tested.
What published studies measured
| Study | System | AMPK-related finding | Tool used |
|---|---|---|---|
| Lee 2015[2] | Cells and mice | Folate cycle and purine biosynthesis inhibited, leading to AMPK activation | Metabolic readouts and AMPK activation |
| Kim 2018[3] | Cells under glucose restriction | MOTS-c translocates to the nucleus and regulates nuclear genes in an AMPK-dependent manner | Metabolic stress; AMPK dependence |
| Ming 2016[4] | Ovariectomized mice; osteoclast cultures | MOTS-c raised phosphorylated AMPK; effects on osteoclastogenesis partly abrogated by compound C | AMPK inhibitor compound C |
| Lu 2019[5] | Ovariectomized mice; adipocytes | MOTS-c activated the AMPK pathway; a blocker attenuated its effect on adipocyte lipid metabolism | AMPK pathway blocker |
Four studies from three groups point the same way, but they differ in model, tissue and readout, so they support the idea that AMPK is involved across contexts rather than establishing one pathway in detail.
Readouts that report AMPK activity
- Phospho-AMPK (the catalytic subunit at its activation-loop threonine) normalized to total AMPK. The commonest readout, by immunoblot. Report both bands.
- Phosphorylation of a downstream substrate, such as acetyl-CoA carboxylase, which is an AMPK target in the classic activator work.[6]
- Functional outputs of AMPK, such as reduced fatty acid synthesis and altered lipolysis, which were used when AMPK activation by a nucleoside analog was first characterized.[6]
- Energy-charge measurements (ATP, ADP, AMP), to show whether the peptide changed cellular energy status or acted without doing so.
- Time course. AMPK phosphorylation can rise and fall within minutes to hours, so a single time point is a weak design.
The principle is to pair a phosphorylation readout with a functional readout and with a time course, because phosphorylation alone does not show that the kinase did anything.
Tool compounds: what they can and cannot show
| Compound | Role | What the literature says | Practical caution |
|---|---|---|---|
| AICAR | AMPK activator (positive control) | Taken up and converted to ZMP, which mimics AMP's activating effects, without perturbing cellular ATP, ADP or AMP in the original rat hepatocyte work[6] | Its metabolite ZMP resembles a purine-synthesis intermediate (this is reasoning, not a finding of the cited paper), which could overlap with the folate-purine pathway reported for MOTS-c[2] |
| Compound C (dorsomorphin) | AMPK inhibitor | A review states that it inhibits several other kinases much more potently than AMPK and is therefore highly non-specific[7] | A partial reversal by compound C is suggestive, not proof of AMPK dependence |
| Genetic knockdown or knockout of AMPK catalytic subunits | Loss-of-function control | Cleaner than a pharmacological inhibitor | Requires compensation checks between the two catalytic isoforms |
Two consequences follow for a MOTS-c experiment. First, a positive control that acts through nucleotide metabolism cannot cleanly separate itself from a mechanism that also runs through purine biosynthesis. Second, a compound C result should be regarded as one line of evidence. In the 2016 bone study compound C partially abrogated the effect of MOTS-c on osteoclastogenesis;[4] "partially" is the accurate word, and the review of the reagent's pros and cons explains why a stronger conclusion would need a genetic approach.[7]
Control matrix for an AMPK-dependence experiment
| Arm | Purpose | Interpretation |
|---|---|---|
| Vehicle | Baseline | Reference for every comparison |
| MOTS-c alone | Test effect | Change in phospho-AMPK and function |
| AICAR alone | Positive control | Defines assay's dynamic range |
| Compound C alone | Inhibitor control | Shows effects of inhibitor on its own |
| MOTS-c + compound C | Dependence test | Attenuation suggests, but does not prove, AMPK dependence |
| Scrambled-sequence peptide | Sequence control | Rules out generic peptide effects |
| AMPK-depleted cells + MOTS-c | Genetic dependence test | Loss of effect supports dependence |
Running the inhibitor alone matters because a drug that lowers a readout by itself will also lower it in combination, producing an apparent "reversal" that is just additive.
Medium, stress and timing
The 2018 study reported effects after metabolic stress such as glucose restriction,[3] so the culture medium is part of the experiment. Glucose concentration, serum and the time since the last medium change all change AMPK baseline activity. Plates should receive identical medium changes, and cells should be exposed at similar confluence. Report the medium composition and the timing in the methods; these details decide whether another laboratory sees the same baseline. For related nuclear findings see MOTS-c nuclear translocation research background.
Concentration arithmetic, formula only
Stock concentration (mmol/mL) = mass (mg) ÷ molecular weight (g/mol) ÷ volume (mL), and the formula weight of MOTS-c is about 2,175 g/mol (formula C101H152N28O22S2 on the product page). Use the calculator. The two methionines in the sequence can oxidize, which lowers the amount of intact peptide, so prepare dilute solutions fresh, keep lyophilized material at 2-8 °C or −20 °C for long-term storage as the product page states, and compare lots with the COA library where a lot is published. Handling reasoning is in MOTS-c reconstitution and storage.
Interpreting a negative or partial result
Not every AMPK experiment will show a clean activation, and the interpretation of a null result deserves as much care as that of a positive. If phospho-AMPK does not rise, the possibilities include a cell type or medium in which the pathway is already maximally active, a time point that missed the peak, insufficient intact peptide because of oxidation, and a genuine absence of effect. Checking the positive control, extending the time course and verifying the material by mass spectrometry separate these. If compound C only partly reverses an effect, the honest report is "partly reversed by a non-specific inhibitor", with the genetic experiment named as the next step.
Research-use statement
All material discussed here is supplied for laboratory research use only; not for human or animal consumption, and not a drug, food or cosmetic.
Related reading
- MOTS-c research overview: the pillar guide
- MOTS-c product page: size, purity, lot COA and storage line
- What is MOTS-c peptide?
- MOTS-c vs other mitochondrial-derived peptides
- MOTS-c AMPK pathway research background
- MOTS-c nuclear translocation research background
- MOTS-c reconstitution and storage
- MOTS-c purity testing
- Browse all research compounds
Frequently asked questions
What should a negative AMPK result prompt?
Check the positive control, extend the time course and verify the intact peptide before concluding there is no effect.
What did the 2015 study report about AMPK?
That MOTS-c cellular actions inhibit the folate cycle and de novo purine biosynthesis, leading to AMPK activation.[2]
Which readout is standard for AMPK activity?
Phospho-AMPK normalized to total AMPK, ideally with a downstream substrate and a functional readout.[6]
What is AICAR used for?
As an AMPK activator and positive control; it is converted to ZMP, which mimics AMP.[6]
Is compound C a clean AMPK inhibitor?
No. A review states that it inhibits several other kinases much more potently than AMPK and is highly non-specific.[7]
Did compound C block MOTS-c effects in published work?
Partially, in the osteoclastogenesis study[4] and in the adipocyte study with an AMPK pathway blocker.[5]
Why include a compound-C-alone arm?
Because an inhibitor that lowers the readout by itself will appear to reverse a peptide effect when combined.
Why does glucose restriction matter?
The nuclear-regulation study used metabolic stress such as glucose restriction, so medium composition is part of the design.[3]
Why use a time course?
AMPK phosphorylation is dynamic, so a single time point can miss or exaggerate an effect.
How is a stock calculated?
Mass in mg divided by about 2,175 g/mol, divided by volume in mL; the calculator does it.
Is MOTS-c intended for people or animals?
No. It is supplied for laboratory research use only; not for human or animal consumption.
Related reading: MOTS-c, Exercise and Skeletal Muscle: Published Data, MOTS-c, Glucose Metabolism and Insulin Resistance Assays, MOTS-c in High-Fat-Diet Mice: Model Design Guide.
References
- Hardie DG, et al. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012. doi:10.1038/nrm3311 PMID: 22436748
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. doi:10.1016/j.cmet.2015.02.009 PMID: 25738459
- Kim KH, et al. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018. doi:10.1016/j.cmet.2018.06.008 PMID: 29983246
- Ming GF, et al. Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation. Biochem Biophys Res Commun. 2016. doi:10.1016/j.bbrc.2016.05.135 PMID: 27237975
- Lu H, et al. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. J Mol Med. 2019. doi:10.1007/s00109-018-01738-w PMID: 30725119
- Corton JM, et al. 5-Aminoimidazole-4-carboxamide ribonucleoside: a specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem. 1995. doi:10.1111/j.1432-1033.1995.tb20498.x PMID: 7744080
- Dasgupta B, et al. Compound C/dorsomorphin: its use and misuse as an AMPK inhibitor. Methods Mol Biol. 2018. doi:10.1007/978-1-4939-7598-3_12 PMID: 29480476
